Elobixibat (BioDeep_00000837772)
代谢物信息卡片
化学式: C36H45N3O7S2 (695.2699)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)NC(C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC
InChI: InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C177170 - Ileal Bile Acid Transport Inhibitor
A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10796
- PubChem: 9939892
- DrugBank: DB12486
- ChEMBL: CHEMBL3039515
- CAS: 439087-18-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Michihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, Anna Ozaki, Yuki Kasai, Takashi Kobayashi, Asako Nogami, Yasushi Honda, Yuji Ogawa, Kento Imajo, Haruki Usuda, Koichiro Wada, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima, Masato Yoneda. Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease.
Hepatology communications.
2023 11; 7(11):. doi:
10.1097/hc9.0000000000000285. [PMID: 37902528] - Satoko Yoshinobu, Nao Hasuzawa, Ayako Nagayama, Shimpei Iwata, Junichi Yasuda, Rie Tokubuchi, Masaharu Kabashima, Mizuki Gobaru, Kento Hara, Kenta Murotani, Yoshinori Moriyama, Kenji Ashida, Masatoshi Nomura. Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM.
Clinical therapeutics.
2022 10; 44(10):1418-1426. doi:
10.1016/j.clinthera.2022.08.009. [PMID: 36117045] - Yoshiaki Hishida, Yoshio Nagai, Hidekazu Tsukiyama, Yuta Nakamura, Tomoko Nakagawa, Sonoko Ishizaki, Yasushi Tanaka, Masakatsu Sone. Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study.
Advances in therapy.
2022 Jul; ?(?):. doi:
10.1007/s12325-022-02243-w. [PMID: 35867276] - Atsushi Nakajima, Sonoko Ishizaki, Kazuki Matsuda, Shinsuke Kurosu, Shinya Taniguchi, Per-Göran Gillberg, Jan P Mattsson, Tomoko Hasunuma, Michael Camilleri. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
Journal of gastroenterology and hepatology.
2022 May; 37(5):883-890. doi:
10.1111/jgh.15800. [PMID: 35168298] - Ryo Yamauchi, Hidetoshi Takedatsu, Keiji Yokoyama, Eri Yamauchi, Motoko Kawashima, Takahiro Nagata, Yotaro Uchida, Takanori Kitaguchi, Tomotaka Higashi, Hiromi Fukuda, Naoaki Tsuchiya, Kazuhide Takata, Takashi Tanaka, Daisuke Morihara, Yasuaki Takeyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice.
Hepatology international.
2021 Apr; 15(2):392-404. doi:
10.1007/s12072-020-10107-0. [PMID: 33398776] - Noboru Misawa, Takuma Higurashi, Tomohiro Takatsu, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Keiichi Ashikari, Takaomi Kessoku, Akiko Fuyuki, Tetsuya Matsuura, Hidenori Ohkubo, Haruki Usuda, Koichiro Wada, Nakayuki Naritaka, Hajime Takei, Hiroshi Nittono, Mitsuharu Matsumoto, Akira Honda, Atsushi Nakajima, Michael Camilleri. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Alimentary pharmacology & therapeutics.
2020 09; 52(5):821-828. doi:
10.1111/apt.15950. [PMID: 32687674] - Daigo Kamei, Yuiko Kamei, Masashi Nagano, Michio Mineshima, Kosaku Nitta, Ken Tsuchiya. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
BMC gastroenterology.
2020 Jan; 20(1):26. doi:
10.1186/s12876-020-1179-6. [PMID: 32005162] - Yuji Kumagai, Hideki Amano, Yoshinobu Sasaki, Chie Nakagawa, Mika Maeda, Ichiro Oikawa, Hidetoshi Furuie. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
British journal of clinical pharmacology.
2018 10; 84(10):2393-2404. doi:
10.1111/bcp.13698. [PMID: 29959787] - Victor Chedid, Priya Vijayvargiya, Michael Camilleri. Elobixibat for the treatment of constipation.
Expert review of gastroenterology & hepatology.
2018 Oct; 12(10):951-960. doi:
10.1080/17474124.2018.1522248. [PMID: 30204504] - Philip B Miner. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
Expert opinion on pharmacotherapy.
2018 Aug; 19(12):1381-1388. doi:
10.1080/14656566.2018.1508450. [PMID: 30129377] - Mats Rudling, Michael Camilleri, Hans Graffner, Jens Juul Holst, Leif Rikner. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
BMC cardiovascular disorders.
2015 Jul; 15(?):75. doi:
10.1186/s12872-015-0070-9. [PMID: 26197999] - Banny S Wong, Michael Camilleri. Elobixibat for the treatment of constipation.
Expert opinion on investigational drugs.
2013 Feb; 22(2):277-84. doi:
10.1517/13543784.2013.753056. [PMID: 23215781]
